Dyne Therapeutics maintains a strong $1.1B cash position, funding operations into mid-2028 despite heavy R&D and operating ...

Dyne announced the results of new analyses of cardiac and pulmonary function amongst all DELIVER participants who were randomized to z-rostudirsen treatment at baseline (any dose 1) and for whom ...

HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 -- 48-week trial will enroll approximately 150 ...

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced presentations on SGT-003, its ...

Abstract: In Asia, the availability of school counselors is significantly lower than global standards recommend, particularly in elementary education settings. This shortage is exacerbated by rising ...

There is a process to a patient being diagnosed with a rare condition and then collaborating with their physician, if they are fortunate enough to have that opporunity. One recent qualitative study ...

Abstract: Benign Paroxysmal Positional Vertigo (BPPV) is an inner ear disorder characterized by dizziness and a sense of imbalance, resulting from a disturbance in the balance center located in the ...